Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:03 2022-12-07 pm EST
104.81 USD   +0.91%
12/02Reckitt expects U.S. infant formula shortage until spring
RE
12/01Reckitt expects U.S. infant formula shortage until spring
RE
12/01Enfamil maker Reckitt sees formula shortage continuing until Spring
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
107.93(c) 108.09(c) 105.41(c) 103.86(c) 104.81(c) Last
5 076 191 4 944 080 4 687 130 4 175 718 3 592 423 Volume
+0.33% +0.15% -2.48% -1.47% +0.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 43 181 M - -
Net income 2022 6 845 M - -
Net Debt 2022 4 483 M - -
P/E ratio 2022 27,1x
Yield 2022 1,78%
Sales 2023 39 673 M - -
Net income 2023 6 121 M - -
Net Debt 2023 1 103 M - -
P/E ratio 2023 30,7x
Yield 2023 1,81%
Capitalization 183 B 183 B -
EV / Sales 2022 4,34x
EV / Sales 2023 4,63x
Nbr of Employees 113 000
Free-Float 87,2%
More Financials
Company
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (36.3%); - vascular devices (33.4%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (19.2%): pediatric nutrition products, nutritional supplements, and... 
More about the company
Ratings of Abbott Laboratories
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ABBOTT LABORATORIES
12/02Reckitt expects U.S. infant formula shortage until spring
RE
12/01Reckitt expects U.S. infant formula shortage until spring
RE
12/01Enfamil maker Reckitt sees formula shortage continuing until Spring
RE
11/25Ypsomed, CamDiab Roll Out Automated Insulin Dosing on Abbott's Glucose Monitoring Syste..
MT
11/21Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable a..
CI
11/17Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
PR
11/10Becton Dickinson expects fiscal 2023 COVID test sales to drag
RE
11/07MedTech Market Leaders Share Their Long-Term Business Strategy at CECP's CEO Investor F..
AQ
11/02NZ's a2 Milk gets temporary approval to export infant milk formula to U.S
RE
11/01ABBOTT LABORATORIES Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/01Baby formula maker Perrigo buying Nestle's Good Start brand, Wisconsin plant
RE
10/26Mizuho Starts Abbott Laboratories at Neutral With $105 Price Target
MT
10/26Reckitt upbeat on sales outlook as prices rise
RE
10/21Abbott Laboratories : Change in Directors or Principal Officers (form 8-K)
AQ
10/21Raymond James Adjusts Abbott Laboratories' Price Target to $109 From $117, Keeps Outper..
MT
More news
News in other languages on ABBOTT LABORATORIES
11/25Ypsomed ajoute une fonctionnalité d'Abbott à son système Mylife Loop
11/25Ypsomed et CamDiab lancent le dosage automatisé de l'insuline sur le système de surveil..
11/21Abbott lance l'autotest VIH Panbio dans les magasins, augmentant ainsi l'accès à un dép..
11/10Becton Dickinson s'attend à ce que les ventes du test COVID pour l'exercice 2023 soient..
11/02La société néo-zélandaise a2 Milk obtient l'autorisation temporaire d'exporter des prép..
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
ETFs positioned on ABBOTT LABORATORIESETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares US Medical Devices (Acc) - USD15.03%0.28%-NC
IShares U.S. Medical Devices ETF - USD15.02%0.84%United_States
Nomura NEXT FUNDS International Equity MSCI...7.18%0.45%-World
Invesco Dynamic Pharmaceuticals ETF - USD5.43%1.90%United_States
BMO MSCI Genomic Innovation Index ETF - CAD4.71%0.00%-NC
More ETFs positioned on ABBOTT LABORATORIES
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 104,81 $
Average target price 116,15 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-25.53%182 744
MEDTRONIC PLC-25.49%102 530
BECTON, DICKINSON AND COMPANY0.29%69 254
DEXCOM, INC.-12.97%45 127
HOYA CORPORATION-20.81%35 377
AMERISOURCEBERGEN CORPORATION28.14%34 825